This week, Isabel catches up with GOLD’s long-time friend Bora Erdemli, Associate Principal and Leader of Medical Affairs Practice, Europe, ZS. She asks Bora to break down the value of the medical affairs function, asking whether it is being properly utilised by pharma organisations. Bora also shares his thoughts on the future of the MSL, what skills new recruits will need to succeed and his top predictions for the next five years in MA.

If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:

• Revealing the true value of medical affairs https://www.emg-gold.com/post/revealing-the-true-value-of-medical-affairs
• Mastering medical affairs https://www.emg-gold.com/post/mastering-medical-affairs
• Darshan Kulkarni on Super reps, ChatGPT and pharma’s future on social media https://www.emg-gold.com/post/podcast-super-reps-chatgpt-and-pharma-s-future-on-social-media

This week, GOLD talks to Darshan Kulkarni, Principal Attorney, The Kulkarni Law Firm, which focuses on regulatory and compliance for life sciences, about key trends in medical affairs and marketing today. He discusses whether MSLs will one day replace sales reps, the role of ChatGPT in healthcare, pharma’s future on social media and much more.

If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:

• The feature Darshan contributed to: Confronting health inequities for transgender patients https://www.emg-gold.com/post/confronting-health-inequities-for-transgender-patients
• A takeover, a tweet and trouble for pharma marketers https://www.emg-gold.com/post/a-takeover-a-tweet-trouble-for-pharma-marketers
• Preparing MSLs for the spotlight https://www.emg-gold.com/post/preparing-msls-for-the-spotlight
• Davidek Herron on 5 ways pharma can ensure omnichannel success https://www.emg-gold.com/post/5-ways-pharma-can-ensure-omnichannel-success-davidek-herron
• Mental health matters in pharma's approach to care https://www.emg-gold.com/post/mental-health-matters-in-pharma-s-approach-to-care

This week, the team shares a teaser of GOLD’s latest catalyst interview with Mina Makar, Senior Vice President, Global Cardiovascular, Renal and Metabolism (CVRM), AstraZeneca. He talks to Isabel about why he decided to leave pharmacy for pharma, his passion for tackling unmet needs and championing the patient perspective as well as his thoughts on how to be an effective leader.

If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:

Catalyst interview: Mina Makar on tackling unmet patient needs https://www.emg-gold.com/post/mina-makar-on-tackling-unmet-patient-needs

Turning patient insights into action https://www.emg-gold.com/post/turning-patient-insights-into-action

Our last catalyst: John Wahba on the medical affairs evolution https://www.emg-gold.com/post/john-wahba-on-the-medical-affairs-evolution

The GOLD Podcast is back for Season 4, and it is returning with a bang as Helena speaks to Kavita Panke, Disease Area Strategy Leader, Neurodegeneration, Janssen. An inspiring pharma leader working in a rapidly evolving area of the industry, Kavita reveals the reasons behind her passion for neuroscience, how to build a high-performing team and her inspiring goals for 2023.

If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:

• The brains behind neurological breakthroughs
• The vast galaxy of neurology https://www.emg-gold.com/post/the-vast-galaxy-of-neurology
• The value of purpose https://www.emg-gold.com/post/the-value-of-purpose
• Claus Zieler on leadership https://www.emg-gold.com/post/claus-zieler-on-leadership

For our fourth and final GOLD Nugget of Season 3, Helena looks back to our Catalyst interview with Reshema Kemps-Polanco, Executive Vice President and US Head, Novartis Oncology, sharing some of Reshema's ideas for tackling clinical trial recruitment gaps, her personal take on Nelson Mandela’s approach to dealing with failure and why she believes equal representation matters in the pharma industry and beyond.

If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:

Reshema’s full episode: Meet GOLD's next catalyst – Reshema Kemps-Polanco https://www.emg-gold.com/post/podcast-meet-gold-s-next-catalyst-visionary-leader-reshema-kemps-polanco Catalyst interview: Reshema Kemps-Polanco on drive, diversity and finding time for family https://www.emg-gold.com/post/reshema-kemps-polanco-on-drive-diversity-and-finding-time-for-family Ripples of change in R&D https://www.emg-gold.com/post/ripples-of-change-in-research-and-development Setting the stage for a more equitable future https://www.emg-gold.com/post/setting-the-stage-for-a-more-equitable-future

Join Helena and Isabel in ringing in the new year with a special episode in which five of our previous guests share their predictions for what could lie ahead for the pharmaceutical industry in 2023. Together, they discuss a broad range of topics including greater implementation of digital health, social media’s impact on the space, new legislation and much more.

If you are interested in learning more about the topic areas discussed in this episode, check out the following content:

Looking forward to the future of pharma https://www.emg-gold.com/post/looking-forward-to-the-future-of-pharma-davidek-herron

Utilising data lakes in pharma https://www.emg-gold.com/post/utilising-data-lakes-in-pharma

Revealing the true value of medical affairs https://www.emg-gold.com/post/revealing-the-true-value-of-medical-affairs

The changing rhythm of digital therapeutics https://www.emg-gold.com/post/the-changing-rhythm-of-digital-therapeutics

Find a handy list of our guests’ full episodes at https://www.emg-gold.com/post/podcast-the-2023-pharma-forecast 

This GOLD Nugget episode sees Helena reflect on some of the best insights offered by Pav Rishiraj, Director and Head of Pharmacovigilance at Ipsen. She shares some of Pav's thoughts on how the often under-recognised field of pharmacovigilance has changed – particularly its rapid evolution during the COVID-19 pandemic – and its importance as a strategic enabler, as well as Pav's advice on what pharma should do to ensure teams feel valued and integral to the businesses they serve.

If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:

Pav’s full episode: Pharmacovigilance past, present and future https://www.emg-gold.com/post/podcast-pharmacovigilance-past-present-and-future

The physics of pharmacovigilance https://www.emg-gold.com/post/the-physics-of-pharmacovigilance

In the second of four special bonus episodes, Helena looks back at GOLD’s conversation with Paul Simms, CEO, Impatient Health. She considers some of the gold nuggets that Paul shared, including insights on the current state of pharma’s reputation and the ways in which pharma can recover and bolster its reputation.

If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:

Paul’s full episode: Unpicking pharma’s reputation in pop culture https://www.emg-gold.com/post/podcast-unpicking-pharma-s-reputation-in-pop-culture

Reframing Pharma’s bad boy reputation https://www.emg-gold.com/post/reframing-pharma-s-bad-boy-reputation

Hear more from Paul:

Is the pharma rep at death's door? https://www.emg-gold.com/post/is-the-pharma-rep-at-death-s-door

The reality of the metaverse https://www.emg-gold.com/post/the-reality-of-the-metaverse

In the first of four special bonus episodes, Helena looks back at the launch episode of Season 3, which featured Dr Juby Jacob-Nara, Vice President and Global Medical Head for Respiratory, Allergy and Gastro-Intestinal Diseases, Sanofi. Helena considers some of the gold nuggets that Juby shared, including insights on the importance of cross-functional experience, team diversity and continual learning.

If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:

Juby’s full episode: Meet GOLD’s new catalyst – medical aficionado Juby Jacob-Nara https://www.emg-gold.com/post/podcast-meet-gold-s-new-catalyst-medical-aficionado-juby-jacob-nara

Catalyst interview: Juby Jacob-Nara on medical affairs https://www.emg-gold.com/post/juby-jacob-nara-on-medical-affairs

Revealing the true value of medical affairs https://www.emg-gold.com/post/revealing-the-true-value-of-medical-affairs

Preparing MSLs for the spotlight https://www.emg-gold.com/post/preparing-msls-for-the-spotlight

This week’s season finale episode welcomes back some friends of the podcast – most of whom we interviewed on the show this year – to reflect on the past 12 months and give us their take on their key highlights. Hear Aliya Omer, Claire Gillis, Robert Grimm, Michele Manto, Paul Simms and Wendy White, unravel the past year in pharma, looking at everything from access challenges to organisational change to huge wins for marketing approaches and sharing some fascinating insights.

If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:

The impact of global instability https://www.emg-gold.com/_files/ugd/b8a9db_a8c25d06ae954bb98e0fa3448f259168.pdf

Behind the headlines of the Inflation Reduction Act https://www.emg-gold.com/post/behind-the-headlines-of-the-inflation-reduction-act

Revealing the true value of medical affairs https://www.emg-gold.com/post/revealing-the-true-value-of-medical-affairs

Embracing pharma's digital transformation https://www.emg-gold.com/post/embracing-pharma-s-digital-transformation

Elevating pharma’s parental leave policies https://www.emg-gold.com/post/elevating-pharma-s-parental-leave-policies